Chr. Hansen enters first collaboration on production of a next generation probiotic from the Human Microbiome

Chr. Hansen enters first collaboration on production of a next generation probiotic from the Human Microbiome
Press Release | Jan 14. 2016 07:08 GMT

Bacteria that live in and on our bodies outnumber the number of human cells by 10 to 1. There is an increased awareness that these bacteria, called the microbiome, play a crucial role in human health and diseases. Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic, gastrointestinal and other diseases. Today, Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.

Recent studies have demonstrated the involvement of the intestinal microbiota in insulin resistance. Caelus Health have identified and patented a single species, E. hallii, which through preclinical studies has proven to be capable of reducing insulin resistance, a primary symptom of type 2 diabetes. Caelus’ lead strain, CP-001, is a formulation of E. hallii and is currently in phase I clinical study.

The objective of the collaboration between Chr. Hansen and Caelus Health is to develop a CP-001 product formulation that will allow for progression to a phase II clinical trial and a subsequent market introduction. As part of this collaboration, Chr. Hansen will develop a production process and pilot material for clinical trials which Caelus Health will run to explore the use of Eubacterium hallii for prevention and treatment of metabolic disease

First of several projects within the Human Microbiome space

Johan van Hylckama Vlieg PhD, Senior Director, Microbiome, Chr. Hansen, says: “Chr. Hansen has unparalleled expertise in fermentation and food and pharma grade production of bacteria. The collaboration with Caelus is in full alignment with our strategy to become the partner of choice for companies wanting to develop new generations of probiotic products and therapeutic microbes. The agreement with Caelus is an important milestone as the first of several projects within the Human Microbiome space for Chr. Hansen”

Luc Sterkman MD, CEO, Caelus states: “We are very pleased to announce this cooperation and are confident that Chr. Hansen has all the expertise and capabilities to develop an advanced formulation of CP-001, which we will further study in upcoming phase 2 clinical studies. This E. hallii based product is the first of a series of Microbiome-based products, which Caelus plans to bring to the market.”


For more information please contact:

Chr. Hansen: Klara Halkjaer,
dkklha@chr-hansen.com
+45 53 39 23 62

Cealus Health: LGW Sterkman
l.sterkman@caelushealth.com
+31-6-22979249

***

Caelus Health is an Amsterdam-based biotech company. Caelus is dedicated to the commercialisation of functional food and pharmaceutical products for the prevention and early treatment of cardio-metabolic diseases. Based on the strong correlation between the intestinal microbiome and health, the company is developing an entirely new class of microbiota-based therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes Mellitus (T2DM) in people with metabolic syndrome (MetS). The first product is now in clinical phase of development and is based on Eubacterium hallii. Life Sciences Fund Amsterdam (LSFA) is the founding investor.


科 汉森是一家全球性且具备差异化的生物科技公司,为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森,我们拥有独特的优势,可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里,我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力,库存广泛且价值重大,包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外,我们还将挖掘释放有益菌的力量,以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司,我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动,公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。

NewsAttachments

共享